EQT confirms recommended bid for Qiagen worth €10.8bn
EQT XI, along with ADIA and CPP Investments, has made a €10.8bn recommended bid for Qiagen. Qiagen's boards approved the deal, which requires 50% shareholder acceptance and is expected to close in mid-2027. Qiagen reported Q3 revenue of $548m and adjusted EPS of $0.65, but withdrew its 2026 forecast.
How this was made
The 30-second read
Why it matters
The bid sets a valuation benchmark for the sector and may trigger competitive offers or shareholder activism.
Market read
First‑report M&A announcement with significant premium; creates immediate trading catalyst for Qiagen.
What to watch
Currency risk from euro‑dollar conversion and integration challenges for EQT's portfolio.
Background
EQT, a private‑equity firm, together with ADIA and CPP Investments, proposes to acquire Qiagen, a leading molecular diagnostics company.
Ticker impact
EQT announced a €10.8bn recommended bid for Qiagen, with board approval and a 50%+ share acceptance condition.
potential upside if the transaction closes, pressure on downside if shareholders reject the offer
Large premium bid disclosed for the first time; market will price in acquisition probability.
Market effects
Potential consolidation in the molecular diagnostics sector, may boost peers with similar technology.
European biotech market could see increased M&A activity.
Large cross‑border deal highlights private‑equity interest in biotech, influencing global sentiment.
Counterpoint
Deal could face regulatory hurdles or financing delays, risking a pull‑back in Qiagen shares.
Key entities
- Private Equity FirmEQT
Bidder leading the €10.8bn acquisition proposal.
- Biotech CompanyQiagen
Target of the acquisition, listed on NASDAQ under QGEN.
